Patents by Inventor Dmitry Kravchenko

Dmitry Kravchenko has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240379188
    Abstract: Aspects of the disclosure relate to methods for improving compatibility of nucleic acid sequencing data obtained using different techniques. The disclosure is based, in part, on methods for mapping expression levels for genes expressed in a biological sample and obtained from a subject using a first protocol to expression levels as would have been determined through a second protocol if the second protocol were used to process the biological sample instead of the first protocol.
    Type: Application
    Filed: May 18, 2022
    Publication date: November 14, 2024
    Applicant: BostonGene Corporation
    Inventors: Nikita Kotlov, Kirill Shaposhnikov, Maksim Chelushkin, IIya Cheremushkin, Artur Baisangurov, Svetlana Podsvirova, Svetlana Khorkova, Dmitry Kravchenko, Cagdas Tazearslan, Alexander Bagaev, Ekaterina Postovalova
  • Patent number: 11838307
    Abstract: Implementations include evaluating a first sub-set of rules based on a first sub-set of facts to provide a first set of impacts, evaluating including applying the first sub-set of facts to each rule using a hash join operation to determine whether a rule results in an impact, indexes of arguments of facts being used in a probe phase of the hash join operation, evaluating a second sub-set of rules using impacts of the first set of impacts to provide a second set of impacts, determining whether each goal in a set of goals has been achieved using the first set of impacts and the second set of impacts, each goal being provided as an impact, in response to determining that each goal in the set of goals has been achieved, removing paths of the AAG, each of the paths resulting in an impact that is not a goal.
    Type: Grant
    Filed: July 1, 2022
    Date of Patent: December 5, 2023
    Assignee: Accenture Global Solutions Limited
    Inventors: Alexander Basovskiy, Dmitry Kravchenko, Avraham Dayan, Moshe Hadad
  • Patent number: 11750657
    Abstract: Implementations include receiving an AAG that at least partially defines a digital twin of an enterprise network and includes rule nodes each representing an attack tactic that can be used to move along a path, determining security controls each mitigating at least one rule node, executing an iteration of a simulation of a sub-set of security controls in the enterprise network, the iteration including: for each security control in the set of security controls, determining, an influence score that represents a change in a security risk from implementing the security control and a rule distribution, defining the sub-set of security controls based on the first influence scores, and reducing the AAG based on the sub-set of security controls to provide a residual AAG, determining a decrease in a graph risk value and the first AAG, and selectively implementing the sub-set of security controls in the enterprise network.
    Type: Grant
    Filed: February 26, 2021
    Date of Patent: September 5, 2023
    Assignee: Accenture Global Solutions Limited
    Inventors: Eitan Hadar, Alexander Basovskiy, Dmitry Kravchenko, Dan Klein
  • Publication number: 20230132030
    Abstract: Aspects of the disclosure relate to methods for determining whether or a subject is likely to respond to certain adoptive cell therapies (e.g., chimeric antigen receptor (CAR) T-cell therapy, etc.). In some embodiments, the methods comprise the steps of identifying a subject as having a tumor microenvironment (TME) type based upon a molecular-functional (MF) expression signature of the subject, and determining whether or not the subject is likely to respond to a chimeric antigen receptor (CAR) T-cell therapy based upon the TME type. In some embodiments, the methods comprise determining the lymphoma microenvironment (LME) type of a lymphoma (e.g., Diffuse Large B cell lymphoma (DLBCL)) subject and identifying the subjects prognosis based upon the LME type determination.
    Type: Application
    Filed: December 23, 2022
    Publication date: April 27, 2023
    Applicant: BostonGene Corporation
    Inventors: Nikita Kotlov, Georgy Sagaradze, Alexander Bagaev, Grigorii Nos, Lev Begniagin, Dmitry Kravchenko, Anna Gribkova
  • Patent number: 11568959
    Abstract: Aspects of the disclosure relate to methods for determining whether or a subject is likely to respond to certain adoptive cell therapies (e.g., chimeric antigen receptor (CAR) T-cell therapy, etc.). In some embodiments, the methods comprise the steps of identifying a subject as having a tumor microenvironment (TME) type based upon a molecular-functional (MF) expression signature of the subject, and determining whether or not the subject is likely to respond to a chimeric antigen receptor (CAR) T-cell therapy based upon the TME type. In some embodiments, the methods comprise determining the lymphoma microenvironment (LME) type of a lymphoma (e.g., Diffuse Large B cell lymphoma (DLBCL)) subject and identifying the subject's prognosis based upon the LME type determination.
    Type: Grant
    Filed: July 6, 2021
    Date of Patent: January 31, 2023
    Assignee: BostonGene Corporation
    Inventors: Nikita Kotlov, Georgy Sagaradze, Alexander Bagaev, Grigorii Nos, Lev Bedniagin, Dmitry Kravchenko, Anna Gribkova
  • Publication number: 20220375543
    Abstract: Aspects of the disclosure relate to methods for improving compatibility of nucleic acid sequencing data obtained using different techniques. The disclosure is based, in part, on methods for mapping expression levels for genes expressed in a biological sample and obtained from a subject using a first protocol to expression levels as would have been determined through a second protocol if the second protocol were used to process the biological sample instead of the first protocol.
    Type: Application
    Filed: May 18, 2022
    Publication date: November 24, 2022
    Inventors: Nikita Kotlov, Kirill Shaposhnikov, Maksim Chelushkin, Ilya Cheremushkin, Artur Baisangurov, Svetlana Podsvirova, Svetlana Khorkova, Dmitry Kravchenko, Cagdas Tazearslan, Alexander Bagaev, Ekaterina Postovalova
  • Publication number: 20220337617
    Abstract: Implementations include evaluating a first sub-set of rules based on a first sub-set of facts to provide a first set of impacts, evaluating including applying the first sub-set of facts to each rule using a hash join operation to determine whether a rule results in an impact, indexes of arguments of facts being used in a probe phase of the hash join operation, evaluating a second sub-set of rules using impacts of the first set of impacts to provide a second set of impacts, determining whether each goal in a set of goals has been achieved using the first set of impacts and the second set of impacts, each goal being provided as an impact, in response to determining that each goal in the set of goals has been achieved, removing paths of the AAG, each of the paths resulting in an impact that is not a goal.
    Type: Application
    Filed: July 1, 2022
    Publication date: October 20, 2022
    Inventors: Alexander Basovskiy, Dmitry Kravchenko, Avraham Dayan, Moshe Hadad
  • Patent number: 11411976
    Abstract: Implementations include evaluating a first sub-set of rules based on a first sub-set of facts to provide a first set of impacts, evaluating including applying the first sub-set of facts to each rule using a hash join operation to determine whether a rule results in an impact, indexes of arguments of facts being used in a probe phase of the hash join operation, evaluating a second sub-set of rules using impacts of the first set of impacts to provide a second set of impacts, determining whether each goal in a set of goals has been achieved using the first set of impacts and the second set of impacts, each goal being provided as an impact, in response to determining that each goal in the set of goals has been achieved, removing paths of the AAG, each of the paths resulting in an impact that is not a goal.
    Type: Grant
    Filed: July 9, 2020
    Date of Patent: August 9, 2022
    Assignee: Accenture Global Solutions Limited
    Inventors: Alexander Basovskiy, Dmitry Kravchenko, Avraham Dayan, Moshe Hadad
  • Publication number: 20220014534
    Abstract: Implementations include evaluating a first sub-set of rules based on a first sub-set of facts to provide a first set of impacts, evaluating including applying the first sub-set of facts to each rule using a hash join operation to determine whether a rule results in an impact, indexes of arguments of facts being used in a probe phase of the hash join operation, evaluating a second sub-set of rules using impacts of the first set of impacts to provide a second set of impacts, determining whether each goal in a set of goals has been achieved using the first set of impacts and the second set of impacts, each goal being provided as an impact, in response to determining that each goal in the set of goals has been achieved, removing paths of the AAG, each of the paths resulting in an impact that is not a goal.
    Type: Application
    Filed: July 9, 2020
    Publication date: January 13, 2022
    Inventors: Alexander Basovskiy, Dmitry Kravchenko, Avraham Dayan, Moshe Hadad
  • Publication number: 20220005551
    Abstract: Aspects of the disclosure relate to methods for determining whether or a subject is likely to respond to certain adoptive cell therapies (e.g., chimeric antigen receptor (CAR) T-cell therapy, etc.). In some embodiments, the methods comprise the steps of identifying a subject as having a tumor microenvironment (TME) type based upon a molecular-functional (MF) expression signature of the subject, and determining whether or not the subject is likely to respond to a chimeric antigen receptor (CAR) T-cell therapy based upon the TME type. In some embodiments, the methods comprise determining the lymphoma microenvironment (LME) type of a lymphoma (e.g., Diffuse Large B cell lymphoma (DLBCL)) subject and identifying the subject's prognosis based upon the LME type determination.
    Type: Application
    Filed: July 6, 2021
    Publication date: January 6, 2022
    Applicant: BostonGene Corporation
    Inventors: Nikita Kotlov, Georgy Sagaradze, Alexander Bagaev, Grigorii Nos, Lev Bedniagin, Dmitry Kravchenko, Anna Gribkova
  • Publication number: 20210273978
    Abstract: Implementations include receiving an AAG that at least partially defines a digital twin of an enterprise network and includes rule nodes each representing an attack tactic that can be used to move along a path, determining security controls each mitigating at least one rule node, executing an iteration of a simulation of a sub-set of security controls in the enterprise network, the iteration including: for each security control in the set of security controls, determining, an influence score that represents a change in a security risk from implementing the security control and a rule distribution, defining the sub-set of security controls based on the first influence scores, and reducing the AAG based on the sub-set of security controls to provide a residual AAG, determining a decrease in a graph risk value and the first AAG, and selectively implementing the sub-set of security controls in the enterprise network.
    Type: Application
    Filed: February 26, 2021
    Publication date: September 2, 2021
    Inventors: Eitan Hadar, Alexander Basovskiy, Dmitry Kravchenko, Dan Klein